ImmunityBio (NASDAQ:IBRX) Shares Down 17.4% on Insider Selling

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) traded down 17.4% during trading on Wednesday following insider selling activity. The company traded as low as $9.38 and last traded at $9.54. 79,731,023 shares changed hands during trading, an increase of 73% from the average session volume of 46,170,664 shares. The stock had previously closed at $11.55.

Specifically, Director Barry J. Simon sold 10,000 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $9.25, for a total value of $92,500.00. Following the completion of the sale, the director owned 3,081,604 shares of the company’s stock, valued at approximately $28,504,837. The trade was a 0.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the transaction, the director directly owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In other news, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Jefferies Financial Group lifted their price objective on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday. BTIG Research boosted their price target on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Piper Sandler raised their price objective on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial adoption drove a multi‑hundred percent revenue increase, the headline catalyst for the recent rally — investors are treating this as evidence sales are scaling. Read More.
• Positive Sentiment: Multiple outlets report ~600–700% YoY revenue growth attributed to ANKTIVA uptake, reinforcing momentum and driving buying interest. Read More.
• Positive Sentiment: Regulatory/approval expansions and new commercial partnerships for ANKTIVA broaden the company’s global market opportunity—supports multi‑region revenue upside. Read More.
• Positive Sentiment: Q4 results beat consensus (smaller EPS loss and stronger revenue), which validated the commercial story in the near term and triggered bullish analyst notes. Read More.
• Neutral Sentiment: Analysis pieces highlight a disconnect between clinical progress, long‑term fundamentals and extreme short‑term price moves — useful context for risk/reward but not an immediate catalyst. Read More.
• Neutral Sentiment: Analysts (including HC Wainwright) kept bullish long‑term targets while adjusting near‑term EPS — supports a multi‑year upside thesis but adds short‑term uncertainty. Read More.
• Negative Sentiment: Insider selling: Director Barry J. Simon and others sold significant blocks in recent days, which can signal profit‑taking and weigh on sentiment. Read More.
• Negative Sentiment: Company remains unprofitable and consensus still forecasts a net loss for the current year — valuation and execution risks remain if commercial growth stalls. Read More.

ImmunityBio Price Performance

The stock has a 50 day simple moving average of $4.97 and a two-hundred day simple moving average of $3.28. The company has a market cap of $9.81 billion, a price-to-earnings ratio of -25.11 and a beta of 0.16.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, research analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently bought and sold shares of the company. Slow Capital Inc. acquired a new stake in shares of ImmunityBio during the 3rd quarter worth approximately $25,000. Truist Financial Corp purchased a new position in ImmunityBio in the third quarter worth approximately $27,000. Swiss Life Asset Management Ltd acquired a new stake in ImmunityBio during the third quarter worth $27,000. WealthPlan Investment Management LLC purchased a new stake in ImmunityBio in the fourth quarter valued at $27,000. Finally, Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio in the 2nd quarter valued at $27,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.